Our group provides support on genetic testing through karyotypic analysis, fluorescence “in situ” hybridization, comparative genomic hybridization, microarrays and next generation sequencing of cancer patients, to more than 100 hospitals in Spain, and occasionally others from the EU.
We collaborate with the most relevant groups in the treatment of the hematological malignancies such as Pethema, GEL-TAMO, GEM or GETH providing technical support and the characterization of the genetic abnormalities in the patients included in clinical trials.
Our main lines research are:
We work on the determination of molecular markers with a diagnostic and prognostic interest, the identification of genetic mechanisms related to the pathogenesis of malignant haematological disorders, as well as towards the integration of genomic high-throughput technologies for the study of cancer.Read More
Am J Hematol. 2022
Marín-Quílez A. et al.
Centro de Investigación del Cáncer
Hospital Clínico Universitario Salamanca
Edificio Multiusos I+D+i Universidad de Salamanca
+34 923 294 720
+34 923 291 100
+34 923 294 400